SE0100857D0 - Treatment of tumors - Google Patents

Treatment of tumors

Info

Publication number
SE0100857D0
SE0100857D0 SE0100857A SE0100857A SE0100857D0 SE 0100857 D0 SE0100857 D0 SE 0100857D0 SE 0100857 A SE0100857 A SE 0100857A SE 0100857 A SE0100857 A SE 0100857A SE 0100857 D0 SE0100857 D0 SE 0100857D0
Authority
SE
Sweden
Prior art keywords
alpha
androstane
medicament
derivatives
androstene
Prior art date
Application number
SE0100857A
Other languages
Swedish (sv)
Inventor
Tomas Hagstroem
Jan-Erling Baeckvall
Peter Soederkvist
Original Assignee
Tomas Hagstroem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tomas Hagstroem filed Critical Tomas Hagstroem
Priority to SE0100857A priority Critical patent/SE0100857D0/en
Publication of SE0100857D0 publication Critical patent/SE0100857D0/en
Priority to AU2002237613A priority patent/AU2002237613B2/en
Priority to EP02704017A priority patent/EP1379542A2/en
Priority to PCT/SE2002/000443 priority patent/WO2002072003A2/en
Priority to JP2002570963A priority patent/JP2004524325A/en
Priority to CA002440973A priority patent/CA2440973A1/en
Priority to US10/658,125 priority patent/US20050192262A1/en
Priority to US11/609,643 priority patent/US20070111973A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0014—Androstane derivatives substituted in position 17 alfa, not substituted in position 17 beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to steroid derivatives for use as medicaments. More specifically, the invention also relates to the use of a steroid derivative of 5-androstene-, 5-pregnenolone or corresponding saturated derivatives (androstane- or pregnane-) in the manufacture of a medicament for the treatment of a benign and/or malignant tumour, which medicament is capable of interrupting disturbances in Wnt-signaling, such as cell-cycle arrest in G1-phase, and/or providing an angiostatic effect. Examples of such steroid derivatives are DELTA -5-androstene-17 alpha -ol, androstane-17 alpha -ol-pregnane-17 alpha -ol or pregnane-17 alpha -ol derivatives. In a further aspect, the invention relates to a method of producing a medicament for the treatment of a benign and/or malignant tumour and/or an inflammatory condition comprising the steps of contacting 5-androstane-3ss,17 alpha -diol or androstane-3ss alpha -diol, an enzyme and a sulfotransferase to provide 5-androstene-17 alpha -ol-3ss-sulfate or corresponding androstane derivative (17 alpha -AEDS or 17-AADS); and mixing the 17 alpha -AEDS or 17 alpha -AADS so produced with a suitable carrier; whereby a medicament which is capable of acting as a ligand to perox-isome proliferator-activated receptor- gamma (PPAR gamma ) is produced.
SE0100857A 2001-03-13 2001-03-13 Treatment of tumors SE0100857D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
SE0100857A SE0100857D0 (en) 2001-03-13 2001-03-13 Treatment of tumors
AU2002237613A AU2002237613B2 (en) 2001-03-13 2002-03-11 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour
EP02704017A EP1379542A2 (en) 2001-03-13 2002-03-11 Treatment of tumours
PCT/SE2002/000443 WO2002072003A2 (en) 2001-03-13 2002-03-11 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour
JP2002570963A JP2004524325A (en) 2001-03-13 2002-03-11 Use of steroid derivatives for the treatment of benign and / or malignant tumors
CA002440973A CA2440973A1 (en) 2001-03-13 2002-03-11 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour
US10/658,125 US20050192262A1 (en) 2001-03-13 2003-09-09 Treatment of tumours
US11/609,643 US20070111973A1 (en) 2001-03-13 2006-12-12 Treatment of tumours

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0100857A SE0100857D0 (en) 2001-03-13 2001-03-13 Treatment of tumors

Publications (1)

Publication Number Publication Date
SE0100857D0 true SE0100857D0 (en) 2001-03-13

Family

ID=20283329

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0100857A SE0100857D0 (en) 2001-03-13 2001-03-13 Treatment of tumors

Country Status (6)

Country Link
EP (1) EP1379542A2 (en)
JP (1) JP2004524325A (en)
AU (1) AU2002237613B2 (en)
CA (1) CA2440973A1 (en)
SE (1) SE0100857D0 (en)
WO (1) WO2002072003A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912240A (en) 1997-04-10 1999-06-15 Loria; Roger M. 5-androstene 3β, 17α diol as an inhibitor of tumor growth
DE60324118D1 (en) * 2002-03-21 2008-11-27 Roger M Loria ALPHA AED AND BETA-AED REGULATION OF NUCLEAR TRANSCRIPTION, GENERGULATION AND / OR GENE EXPRESSION
EP1727529B1 (en) 2004-03-17 2016-03-02 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
GB2421183A (en) * 2004-12-17 2006-06-21 Stegram Pharmaceuticals Ltd Topical formulations for use in the treatment or prevention of skin cancers
CA2670957A1 (en) * 2006-11-30 2008-06-05 Hunter-Fleming Limited Modulation of prostaglandin/cyclooxygenase metabolic pathways
RU2593751C2 (en) 2011-05-20 2016-08-10 Энсэрм (Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль) Cb1 receptor antagonists
SI2925770T1 (en) 2012-11-28 2017-07-31 Institut National De La Sante Et De La Recherche Medicale(Inserm) 3-(4'-substituted)-benzyl-ether derivatives of pregnenolone
WO2023246940A1 (en) * 2022-06-24 2023-12-28 Huang Chi Ying Method of treating a cancer through suppression of growth of cancer stem cells, and downregulation of wnt pathway

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912240A (en) * 1997-04-10 1999-06-15 Loria; Roger M. 5-androstene 3β, 17α diol as an inhibitor of tumor growth
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods

Also Published As

Publication number Publication date
AU2002237613B2 (en) 2008-01-03
EP1379542A2 (en) 2004-01-14
WO2002072003A3 (en) 2003-02-20
CA2440973A1 (en) 2002-09-19
JP2004524325A (en) 2004-08-12
WO2002072003A2 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
AU2003282233A1 (en) Quinoline derivatives as glucokinase ligands
WO2003070163A3 (en) Prostacyclin derivatives for treating cancer
PL309225A1 (en) Pharmacologically active derivatives of pyridine and methods of obtaining them
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
MY136761A (en) Oxazol derivatives
AU2003282234A1 (en) Benzofuran derivates, process for their preparation and intermediates thereof
MX9706345A (en) Benzopyran-containing compounds and method for their use.
DK1373215T3 (en) Gelanamycin derivatives suitable for the treatment of cancer
GB0223038D0 (en) Therapeutic compounds
GEP20033140B (en) Substituted Bicyclic Derivatives Useful as Anticancer Agents
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
JP2005505588A5 (en)
NO954996D0 (en) Use of nona and decapeptides for the manufacture of a medicament for the treatment of AIDS
NO20050450L (en) Combination of ZD6474, an inhibitor of vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
SE0100857D0 (en) Treatment of tumors
SE0003476D0 (en) Compounds
AU5705099A (en) Compounds useful as aicarft inhibitors
NO20013414D0 (en) New use of melagatran
ATE360428T1 (en) ANALGESIC MEDICINAL PRODUCT
WO2002064172A3 (en) Fhit gene therapy prevents tumor development in fhit-deficient mice
AU2003281193A1 (en) Quinazoline derivatives for use in the treatment of cancer
WO2002078690A3 (en) Taxoid anti-tumor agents and pharmaceutical compositions thereof
NO20052177L (en) Use of galantamine and its derivatives for the manufacture of drugs
NO20041057L (en) Prophylactic and therapeutic use of hydroxysteroids
MXPA03006359A (en) Method for treating cancer having greater efficacy and reduced adverse effects.